Applied Molecular Transport Announces Pricing of Initial Public Offering
05 6월 2020 - 11:40AM
Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage
biopharmaceutical company, today announced the pricing of its
initial public offering of 11,000,000 shares of common stock at a
public offering price of $14.00 per share. All of the shares of
common stock are being offered by AMT. The gross proceeds of the
offering, before deducting underwriting discounts and commissions
and other offering expenses payable by AMT, are expected to be
$154.0 million, excluding any exercise of the underwriters’ option
to purchase additional shares. The shares are expected to begin
trading on the Nasdaq Global Select Market on June 5, 2020, under
the ticker symbol “AMTI.” The offering is expected to close on June
9, 2020, subject to the satisfaction of customary closing
conditions. In addition, AMT has granted the underwriters a 30-day
option to purchase up to an additional 1,650,000 shares of common
stock at the initial public offering price, less the underwriting
discounts and commissions.
BofA Securities, Jefferies and SVB Leerink are
acting as joint book-running managers for this offering.
Registration statements relating to the shares
being sold in this offering have been filed with the Securities and
Exchange Commission and became effective on June 4, 2020. The
offering will be made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained, when
available, from: BofA Securities, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department, or by email at dg.prospectus_requests@bofa.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone
at (877) 821-7388, or by email at
prospectus_department@Jefferies.com; or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, or by telephone at (800) 808-7525, ext. 6218, or by email
at syndicate@svbleerink.com. Copies of the the final
prospectus, when available, related to the offering will be
available at www.sec.gov.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any offer or sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
such state or jurisdiction.
About Applied Molecular Transport
Inc.
Applied Molecular Transport Inc. is a
clinical-stage biopharmaceutical company leveraging its proprietary
technology platform to design and develop a pipeline of novel oral
biologic product candidates to treat autoimmune, inflammatory,
metabolic, and other diseases. AMT’s proprietary technology
platform allows it to exploit existing natural cellular trafficking
pathways to facilitate the active transport of therapeutic payloads
across the intestinal epithelium (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing oral biologic product candidates in
patient-friendly tablet and capsule forms that are designed for
either targeting local gastrointestinal (GI) tissue or entering
systemic circulation to precisely address the relevant biology of a
disease. AMT is building a portfolio of oral product candidates
based on its technology platform including its lead product
candidate, AMT-101, an oral GI-selective interleukin 10 that has
completed a Phase 1b clinical trial in patients with ulcerative
colitis (UC). AMT further plans to initiate Phase 2 clinical trials
of AMT-101 in UC and related inflammatory indications. AMT’s
technology platform enables it to design and develop various oral
biologic therapeutic modalities, such as peptides, proteins,
full-length antibodies, antibody fragments, and RNA therapeutics,
with potentially significant advantages over existing marketed and
development-stage drugs.
Contacts:
Sylvia WheelerPrincipal, Wheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Alexandra SantosSenior Partner, Wheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024